EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›MLSS

MLSS

MILESTONE SCIENTIFIC INC.

Next earnings Aug 12, 2026 · consensus $-0.01 EPS, $2.55M rev

Sell
$0.32
▼ -0.71%
$0.32▼ -63.67%
over 1Y
L $0.25EODHDH $0.88
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.7%
1W-3.2%
1M-17.0%
3M+20.2%
YTD+8.5%
1Y-63.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
D
Valuation
Fair value
Filings
Flagged
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy

Unprofitable (net margin -63.8%).

MILESTONE SCIENTIFIC INC. shows $8.97M in FY2025 revenue (+4.0% YoY), a -63.8% net margin, and -203.4% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$10.3M$8.81M$9.83M$8.63M$8.97M
Gross profit$6.31M$4.90M$6.79M$6.43M$6.41M
Operating income-$7.38M-$8.83M-$7.11M-$6.76M-$5.70M
Net income-$6.82M-$8.71M-$6.93M-$4.71M-$5.72M
Diluted EPS-$0.10——-$0.06-$0.07
Net margin-66.2%-98.9%-70.5%-54.6%-63.8%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$24.6M
EV / EBITDA—
EV / Sales2.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-22.2%
FCF yield-11.4%

Quality & risk

ROIC (est.)-160.0%
Free cash flow-$2.93M
Total debt—
Net cash$1.11M
Altman Z-Score-21.64 distress
Piotroski F-Score2/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — restated periodic report (2026-05-05). Worth a closer look.
  1. 8-K Officer / director change2026-06-25
  2. DEF 14A Proxy statement2026-06-22
  3. S-3 Shelf registration (potential raise)2026-06-02
  4. 10-Q Quarterly report2026-05-13
  5. 8-K Auditor change2026-05-06
  6. 8-K Officer / director change2026-05-06
  7. 10-K/A Restated periodic report2026-05-05
  8. 8-K Material agreement2026-04-21
  9. 8-K Material agreement2026-04-02

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-04-302026-06-25open ↗DEF 14APeriod ending 2026-06-222026-06-22open ↗PRER14AFiling2026-06-10open ↗EFFECTFiling2026-06-09open ↗424B1Filing2026-06-09open ↗PRE 14APeriod ending 2026-06-052026-06-05open ↗S-3Filing2026-06-02open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-04-302026-05-06open ↗8-KPeriod ending 2026-04-302026-05-06open ↗10-K/APeriod ending 2025-12-312026-05-05open ↗DFiling2026-04-23open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueB
GrowthF
ProfitabilityF
Financial healthC
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$8.97M
+4.0% YoY
Net margin
-63.8%
ROE
-203.4%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$8.97M+4.0%
Net income-$5.72M-21.4%
Gross profit$6.41M-0.4%
Operating income-$5.70M+15.7%
Diluted EPS-$0.07-16.7%
Cash & equivalents$1.11M-65.8%
Total assets$7.81M-20.3%
Total liabilities$4.99M+26.0%
Stockholders' equity$2.81M-51.8%
Gross: 71.4%Op.: -63.5%L/E: 1.78x

Frequently asked

Is MILESTONE SCIENTIFIC INC. (MLSS) a buy?
MLSS currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Unprofitable (net margin -63.8%).
What is MILESTONE SCIENTIFIC INC.'s quality score?
MLSS scores 44.80392156862745/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000855683, latest 10-Q filed 2026-05-13) · EODHD · as of 6/23/2026, 12:49:27 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-10-24
BP4 S.r.l.
10% owner
Sell100K @ $0.44$44.0K
2025-10-23
BP4 S.r.l.
10% owner
Sell80.0K @ $0.43$34.4K
2025-10-22
BP4 S.r.l.
10% owner
Sell14.4K @ $0.45$6.49K
2025-10-21
BP4 S.r.l.
10% owner
Sell40.0K @ $0.44$17.6K
2025-10-20
BP4 S.r.l.
10% owner
Sell24.0K @ $0.45$10.9K
2025-10-14
BP4 S.r.l.
10% owner
Sell30.0K @ $0.54$16.2K
2025-10-13
BP4 S.r.l.
10% owner
Sell10.0K @ $0.55$5.50K
2025-10-10
BP4 S.r.l.
10% owner
Sell10.2K @ $0.55$5.59K
2025-10-08
BP4 S.r.l.
10% owner
Sell30.0K @ $0.47$13.9K
2025-10-07
BP4 S.r.l.
10% owner
Sell10.0K @ $0.45$4.50K
2025-10-03
BP4 S.r.l.
10% owner
Sell9.21K @ $0.45$4.14K
2025-10-03
BP4 S.r.l.
10% owner
Sell10.0K @ $0.45$4.50K

Recent news

market news →
Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain ProceduresBullish
globenewswire.com· 2026-05-27
Milestone Scientific Inc. Q1 2026 Earnings Call SummaryBullish
finance.yahoo.com· 2026-05-14
Earnings Scheduled For May 13, 2026Bullish
finance.yahoo.com· 2026-05-13
Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market CloseBullish
nasdaq.com· 2025-11-14
Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference CallBullish
globenewswire.com· 2025-11-13
Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New LeadershipBullish
globenewswire.com· 2025-10-14

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score45 vs 67
Revenue growth4.0% vs 7.1%
Net margin-63.8% vs 10.5%
Return on equity-203.4% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 3d
Bullish
+0.17
vs typical · 3 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.